Comparing melanoma tumours collected before BRAF inhibitor therapy to resistant tumours in the same patient after therapy identified acquired NRAS mutations in many of these tumours, including in tumours that continue to harbor the BRAF mutations [84]. The gene discussed is NRAS; the disease is neoplasm.